VYNE Investor Relations Presentation
VYNE-Investor-Presentation
VYNE TherapeuticsRooted in Innovation
VYNE Therapeutics
VYNE-Investor-Presentation
KOL Event – Novel InhiBET BET Inhibitor Platform
BRIDGEWATER, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate in Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference on December 8, 2022. Panel Presentation Details Date: Thursday, December 8, 2022 Time: 10:00 to 10:45 a.m. ET Panel Presentation: Hit or Miss: Companies with 2023 Readouts & Launches to Keep in Focus Presenter: David Domzalski, President and Chief Executive Officer…
Statement of changes in beneficial ownership of securities
Other definitive proxy statements
BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, and management will host investor meetings on December 1, 2022. Piper Sandler 34th Annual Healthcare Conference Date: Thursday, December 1, 2022 Time: 12:30 p.m. ET Format: Company presentation 1×1 Meetings: Thursday, December 1, 2022 Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1582698&tp_key=84bac10d55 a replay will…
Notice of Exempt Offering of Securities
BRIDGEWATER, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the first subjects have been dosed in a Phase 1a/b clinical trial evaluating VYN201 for the treatment of vitiligo. VYN201 is a locally administered, small molecule, pan-bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immuno-inflammatory diseases. The clinical trial is a first-in-human study designed to generate safety and pharmacokinetic data in healthy volunteers as well as provide early clinical…